1. Personalized Proteomics: The Future of Precision Medicine
   Trevor Duarte et al, 2016, Proteomes CrossRef
2. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis
   Peggy Barschke et al, 2017, Expert Review of Proteomics CrossRef
3. Serum Proteome in a Sporadic Amyotrophic Lateral Sclerosis Geographical Cluster
   Stefano De Benedetti et al, 2017, Prot. Clin. Appl. CrossRef
4. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
   Csaba Konrad et al, 2017, Mol Neurodegeneration CrossRef
5. Increased motor neuron resilience by small molecule compound that regulate IGF-II expression
   Teresia M. Osborn et al, 2017, Neurobiology of Disease CrossRef
6. Proteomic serum biomarkers for neuromuscular diseases
   Sandra Murphy et al, 2018, Expert Review of Proteomics CrossRef
7. Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects
   Zhouwei Xu et al, 2018, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration CrossRef
8. Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias
   Becky Carlyle et al, 2018, Proteomes CrossRef
9. Current and emerging ALS biomarkers: utility and potential in clinical trials
   Arens Taga et al, 2018, Expert Review of Neurotherapeutics CrossRef
10. Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA)
    Darija Šoltić et al, 2018, Brain Sciences CrossRef
11. Biomarkers in Motor Neuron Disease: A State of the Art Review
    Nick S. Verber et al, 2019, Front. Neurol. CrossRef
12. Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD
    Thomas J. Hedl et al, 2019, Front. Neurosci. CrossRef
13. Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases
    Takashi Hosaka et al, 2019, IJMS CrossRef
14. null
    Mercedes Lachén-Montes et al, 2019 CrossRef
15. Neurochemical biomarkers in amyotrophic lateral sclerosis
    Federico Verde et al, 2019, Current Opinion in Neurology CrossRef
16. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis
    Lucas T. Vu et al, 2017, Neurotherapeutics CrossRef
17. Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients
    Noriko Hayashi et al, 2019, Neuroscience Research CrossRef
18. null
    Katerina Kadena et al, 2020 CrossRef
19. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis
    C. Carlomagno et al, 2020, Sci Rep CrossRef
20. Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Mehdi Ghasemi et al, 2021, Cells CrossRef
21. Development of a Sensitive Bioassay for the Analysis of IGF-Related Activation of AKT/mTOR Signaling in Biological Matrices
    Michael Walz et al, 2021, Cells CrossRef
22. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS.
    Sarah Waters et al, 2021, Acta Neuropathol Commun CrossRef
23. A system-wide mislocalization of RNA-binding proteins in motor neurons is a new feature of ALS
    Yu-Ju Liu et al, 2021, Neurobiology of Disease CrossRef
24. null
    Cory J. Holdom et al, 2022 CrossRef
25. Advancing Mechanistic Understanding and Biomarker Development in Amyotrophic Lateral Sclerosis
    Alexander G Thompson et al, 2021, Expert Review of Proteomics CrossRef
26. Blood-Spinal Cord Barrier: Its Role in Spinal Disorders and Emerging Therapeutic Strategies
    Neha Chopra et al, 2021, NeuroSci CrossRef
27. Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases
    Artur Schumacher-Schuh et al, 2022, Front. Neurol. CrossRef
28. Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis
    Jared S. Katzeff et al, 2022 CrossRef
29. Integrated multi-omic data analysis and validation with yeast model show oxidative phosphorylation modulates protein aggregation in amyotrophic lateral sclerosis
    R. Sai Swaroop et al, 2022, Journal of Biomolecular Structure and Dynamics CrossRef
30. The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of Proteomics
    Francesca Vignaroli et al, 2023, Proteomes CrossRef
31. null
    Sara L. Banerjee et al, 2020 CrossRef
32. Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis
    Maruša Barbo et al, 2023, Genes CrossRef
33. Discovery of Biomarkers for Amyotrophic Lateral Sclerosis from Human Cerebrospinal Fluid Using Mass-Spectrometry-Based Proteomics
    Sungtaek Oh et al, 2023, Biomedicines CrossRef
34. Amyotrophic Lateral Sclerosis and Serum Lipid Level Association: A Systematic Review and Meta-Analytic Study
    Teresa Pardo-Moreno et al, 2023, IJMS CrossRef
35. Modelling TDP-43 proteinopathy in Drosophila uncovers shared and neuron-specific targets across ALS and FTD relevant circuits
    R. Keating Godfrey et al, 2023, acta neuropathol commun CrossRef
36. Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy
    Soju Seki et al, 2023, Biomedicines CrossRef
37. Proteomics and mathematical modeling of longitudinal CSF differentiates fast versus slow ALS progression
    Lucas Vu et al, 2023, Ann Clin Transl Neurol CrossRef
38. null
    Saiswaroop Rajaratnam et al, 2024 CrossRef